Atara is applying this one platform to create a robust pipeline. This ORR is consistent with previously published investigator assessed data. We anticipate potential approval of the MAA in the second half of 2022. Data from this Phase 2 study is expected in 2023. Some preclinical testing may continue even after the IND is submitted. In such a case, the clinical trial cannot be conducted in that Member State. We do not expect to generate product revenues in the near future, if at all. Our company was formed in August 2012. Product defects can also occur unexpectedly. As a result, the government has certain rights to these patent rights and technology. We may not be able to protect our intellectual property rights throughout the world. There are currently no FDA- or EMA-approved products for the treatment of EBV+ PTLD. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. As of December 31, 2020, we had 437 employees. These market fluctuations may adversely affect the trading price of our common stock. We generally contract with third parties for the disposal of these materials and wastes. The CCPA may increase our compliance costs and potential liability. Such notice could harm our reputation and our ability to compete. Where state laws are more protective, we have to comply with the stricter provisions.
